GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (NAS:IMUX) » Definitions » Cyclically Adjusted FCF per Share

Immunic (Immunic) Cyclically Adjusted FCF per Share : $-39.76 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Immunic Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Immunic's adjusted free cash flow per share for the three months ended in Dec. 2023 was $-0.318. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-39.76 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-05-01), Immunic's current stock price is $1.29. Immunic's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $-39.76. Immunic's Cyclically Adjusted Price-to-FCF of today is .


Immunic Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Immunic's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunic Cyclically Adjusted FCF per Share Chart

Immunic Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -55.76 -53.64 -39.76

Immunic Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -53.64 -52.17 -49.49 -45.38 -39.76

Competitive Comparison of Immunic's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Immunic's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunic's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunic's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Immunic's Cyclically Adjusted Price-to-FCF falls into.



Immunic Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Immunic's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.318/129.4194*129.4194
=-0.318

Current CPI (Dec. 2023) = 129.4194.

Immunic Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -19.267 99.695 -25.012
201406 -22.626 100.560 -29.120
201409 -21.158 100.428 -27.266
201412 -17.571 99.070 -22.954
201503 -23.673 99.621 -30.754
201506 -27.372 100.684 -35.184
201509 -20.549 100.392 -26.491
201512 -13.062 99.792 -16.940
201603 -13.195 100.470 -16.997
201606 -11.353 101.688 -14.449
201609 -10.317 101.861 -13.108
201612 -11.498 101.863 -14.609
201703 -13.706 102.862 -17.245
201706 -9.745 103.349 -12.203
201709 -9.086 104.136 -11.292
201712 -9.490 104.011 -11.808
201803 -12.487 105.290 -15.349
201806 -11.840 106.317 -14.413
201809 -12.602 106.507 -15.313
201812 -4.394 105.998 -5.365
201903 -6.286 107.251 -7.585
201906 -1.137 108.070 -1.362
201909 -0.598 108.329 -0.714
201912 -0.614 108.420 -0.733
202003 -1.026 108.902 -1.219
202006 -0.731 108.767 -0.870
202009 -0.650 109.815 -0.766
202012 -0.674 109.897 -0.794
202103 -0.612 111.754 -0.709
202106 -1.334 114.631 -1.506
202109 -0.696 115.734 -0.778
202112 -0.792 117.630 -0.871
202203 -0.736 121.301 -0.785
202206 -0.522 125.017 -0.540
202209 -0.447 125.227 -0.462
202212 -0.394 125.222 -0.407
202303 -0.449 127.348 -0.456
202306 -0.450 128.729 -0.452
202309 -0.389 129.860 -0.388
202312 -0.318 129.419 -0.318

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Immunic  (NAS:IMUX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Immunic Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Immunic's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunic (Immunic) Business Description

Industry
Traded in Other Exchanges
Address
1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Executives
Glenn Whaley officer: PAO and Controller C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Richard Alan Rudick director 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK NY 10036
Joerg Neermann director IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Daniel Vitt director, officer: CEO, President IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Monika Maria Toernsen director ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Duane Nash director C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Andreas Muehler officer: Chief Medical Officer 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK CITY NY 10036
Manfred Groeppel officer: Chief Operating Officer IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Barclay A Phillips director C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Tamar D Howson director
Sanjay S Patel officer: Chief Financial Officer 10 N. PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Claudio Nessi 10 percent owner C/O NEOMED, 7 PLACE DU MOLARD, 1204 GENEVA V8 1204
Anne-mari Paster 10 percent owner C/O OMEGA FUND MANAGEMENT, LLC, 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Lsp V Cooperatieve U.a. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV

Immunic (Immunic) Headlines